Keywords: Forest Labs, Nabriva Thera, BC-3781, Antibacterial, Licensing, Acquisition option

Forest acquires rights to Nabriva antibacterial and option to buy firm

Article | 04 June 2012

Print This

US drugmaker Forest Laboratories (NYSE: FRX) says it has entered into an agreement with Austrian biotech firm Nabriva Therapeutics for ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in